This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read IDEAYA Biosciences’s 8K filing here.
About IDEAYA Biosciences
IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.
Recommended Stories
- Five stocks we like better than IDEAYA Biosciences
- Stock Splits, Do They Really Impact Investors?
- Merck: 4 No-Brainer Reasons to Buy This Dip
- 3 Best Fintech Stocks for a Portfolio Boost
- Ackman Announces Major Stake in Uber: Should You Follow His Lead?
- What Does a Stock Split Mean?
- Wells Fargo Upgraded These 3 Stocks—Here’s Why They Stand Out
